healthcare tech firm’s stock faces growth hurdles By Investing.com

TruBridge, Inc. (NASDAQ:TBRG), a healthcare technology company specializing in Electronic Health Records (EHR) and Revenue Cycle Management (RCM) solutions, has been navigating a complex market landscape in recent months. The company’s stock has drawn mixed reactions from analysts as it grapples with internal challenges while pursuing growth opportunities.

Financial Performance and Outlook

TruBridge reported encouraging second-quarter results for 2024, exceeding consensus expectations. The company’s performance was bolstered by a high-margin EHR license sale and in-line bookings. This positive momentum has led to increased confidence in the company’s ability to meet its fiscal year 2024 (FY24) guidance.

Management has reiterated its FY24 guidance, citing that over 90% of the projected revenue for the year is already under contract. This high level of revenue visibility provides a degree of stability and predictability to TruBridge’s financial outlook.

Despite the strong Q2 performance, TruBridge faced some headwinds earlier in the year. Following its first-quarter results, the company reduced its FY24 revenue guidance, which impacted the anticipated profit ramp in the second half of the year. This adjustment led to a 3% decline in share price at the time.

Analysts project varying earnings per share (EPS) figures for TruBridge. For the first fiscal year (FY1), estimates range from -0.40 to -0.11, while for the second fiscal year (FY2), projections are more optimistic, ranging from 0.04 to 0.11. These figures suggest an expectation of improved profitability in the medium term.

Market Position and Strategic Initiatives

TruBridge operates in the competitive U.S. Healthcare Technology & Distribution sector. The company’s focus on EHR and RCM solutions positions it to capitalize on the ongoing digitization of healthcare services and the increasing need for efficient revenue management in healthcare facilities.

A key strategic initiative for TruBridge has been its transition to offshore operations. Analysts view this move positively, noting the potential for significant margin improvements. The company’s management expects cost savings from ongoing RCM offshoring efforts to contribute to a steeper EBITDA growth trajectory in 2025 and beyond.

TruBridge has also been working on stabilizing its client retention across its EHR base. This effort is crucial for maintaining a steady revenue stream and building long-term relationships with healthcare providers.

The company has reported increasing momentum and deal sizes in its RCM pipeline. This growth in the RCM segment could provide a substantial boost to TruBridge’s future revenue and market position.

Challenges and Risks

While TruBridge has shown positive trends in recent months, the company faces several challenges. In August 2024, TruBridge announced a deficiency in its financial reporting. Although the expected impact was considered immaterial, affecting less than 1% of revenues, such issues can potentially undermine investor confidence.

The company’s management is also working to rebuild its track record with investors. This process of regaining trust may take time and could impact the stock’s performance in the short to medium term.

TruBridge operates in a sector that is sensitive to economic uncertainties and changes in healthcare spending. Any broader economic downturn or shifts in healthcare policy could potentially affect the company’s growth prospects.

Bear Case

How might the internal control deficiency impact investor confidence?

The announcement of an internal control deficiency, even if deemed immaterial, could raise concerns among investors about TruBridge’s financial governance. While the company expects to file or re-file promptly without needing restatements to financials, such incidents can create uncertainty. Investors may become more cautious, potentially leading to increased scrutiny of future financial reports and a temporary dampening of enthusiasm for the stock.

What challenges does TruBridge face in meeting its revised FY24 guidance?

TruBridge’s revised FY24 guidance, following a reduction in revenue outlook earlier in the year, presents a challenge for the company. Meeting these targets will require strong execution in the second half of the year. The company must navigate potential headwinds such as competitive pressures in the healthcare technology sector and any unforeseen disruptions in client adoption or retention. Additionally, the less steep growth outlook may make it more difficult for TruBridge to exceed investor expectations, which could limit upside potential for the stock in the near term.

Bull Case

How could TruBridge’s offshore transition improve its profit margins?

TruBridge’s strategic move to offshore operations, particularly in its RCM segment, presents a significant opportunity for margin expansion. By leveraging lower-cost labor markets, the company can potentially reduce its operational expenses without compromising service quality. Analysts expect this initiative to contribute to a steeper EBITDA growth trajectory in 2025 and beyond. As these cost savings materialize, TruBridge could see improved profitability, even if revenue growth remains moderate. This margin expansion could lead to better-than-expected earnings results, potentially driving stock appreciation.

What potential does the growing RCM pipeline offer for future revenue growth?

The reported increasing momentum and deal sizes in TruBridge’s Revenue Cycle Management pipeline signal strong growth potential for this segment. As healthcare providers continue to seek ways to optimize their revenue collection processes, TruBridge’s RCM solutions could see increased demand. Larger deal sizes suggest that the company may be winning contracts with bigger healthcare organizations or expanding its services with existing clients. If TruBridge can successfully convert this pipeline into secured contracts, it could lead to accelerated revenue growth in the coming years, potentially exceeding current market expectations and driving stock performance.

SWOT Analysis

Strengths:

• Strong Q2 2024 financial performance exceeding analyst expectations
• High percentage (>90%) of FY24 revenue already under contract
• Growing RCM bookings and expanding offshore presence
• Stabilizing EHR business segment

Weaknesses:

• Recent internal control deficiency announcement
• Reduced FY24 revenue guidance earlier in the year
• Need for management to rebuild track record with investors
• Negative EPS projections for the near term (FY1)

Opportunities:

• Potential for significant margin improvements from offshore transition
• Growing RCM pipeline with increasing deal sizes
• Expansion of services within existing client base
• Positive EBITDA growth trajectory expected for 2025 and beyond

Threats:

• Competitive pressures in the healthcare technology sector
• Potential impact of economic uncertainties on healthcare spending
• Risk of further internal control issues affecting investor confidence
• Challenges in meeting revised FY24 guidance

Analysts Targets

• RBC (TSX:) Capital Markets (September 17th, 2024): Outperform, $14.00
• RBC Capital Markets (August 13th, 2024): Outperform, $14.00 (raised from $13.00)
• Barclays (LON:) (August 13th, 2024): Equal Weight, $10.00
• Barclays (August 12th, 2024): Equal Weight, $10.00
• Barclays (May 13th, 2024): Equal Weight, $10.00

TruBridge, Inc. faces a mix of opportunities and challenges as it navigates the healthcare technology landscape. While recent financial performance has been encouraging, the company must address internal control issues and work to rebuild investor confidence. The success of its offshore transition and ability to capitalize on the growing RCM pipeline will be crucial factors in determining its future growth trajectory. Investors and analysts will be closely watching TruBridge’s execution in the coming quarters to assess its ability to meet guidance and drive long-term value creation.

This analysis is based on information available up to September 30, 2024.

InvestingPro: Smarter Decisions, Better Returns

Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on TBRG. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore TBRG’s full potential at InvestingPro.

Should you invest in TBRG right now? Consider this first:

Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if TBRG is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.

To evaluate TBRG further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if TBRG appears on our undervalued or overvalued stock lists.

These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.